S6 Insights on”Insilico Medicine, an early force in AI-driven drug R&D, lets IPO plans peter out for second year in a row”

In Today’s News: Insilico Medicine, an early force in AI-driven drug discovery, has decided not to proceed with its IPO plans for the second consecutive year. The biotech startup, which has raised over $400 million in a decade, cited the…




